Piramal Enterprises concludes acquisition of drug portfolio from Mallinckrodt

20 Mar 2017 Evaluate

Piramal Enterprises’ (PEL) wholly owned Critical Care subsidiary in UK has completed its acquisition of a portfolio of drugs for spasticity and pain management from Mallinckrodt LLC (Mallinckrodt). The acquisition was for a cash consideration of $171 million and up to an additional $32 million payable depending on financial performance of the acquired assets over the next three years.

The portfolio acquired includes Gablofen (baclofen), a severe spasticity management product, which is currently marketed in the United States, and two pain management products, which are currently under development. Gablofen has also been approved for launch in eight European markets. In the twelve months ending September 30, 2016, the acquired portfolio generated revenues of $44.6 million.

Piramal Enterprises is one of India’s large diversified companies, with a presence in Pharmaceuticals, Healthcare Information Management and Financial Services.  


Piramal Ent - Amalga Share Price

1124.60 0.00 (0.00%)
22-Sep-2025 16:59 View Price Chart
Peers
Company Name CMP
Bajaj Finance 998.50
Shriram Finance 848.25
Aditya Birla Capital 347.80
Chola Invest & Fin. 1714.15
Tata Capital 326.25
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×